Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Trial Profile

Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Hemay 022 (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Tianjin Hemay Pharmaceutical Sci-Tech
  • Most Recent Events

    • 23 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 21 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top